Drug factory · FDA FEI 3008772184
Boehringer Ingelheim España, S.A.
Prat de la Riba, 50, Sant Cugat del Vallés, Spain
Problems found, fixed voluntarily at FDA's last inspection, Jun 30, 2023.
Voluntary Action Indicated: inspectors found problems, but not serious enough for FDA to take action. The company is expected to fix them.
1 drug inspection on record since 2023: 0 with no problems, 1 with problems fixed voluntarily, 0 with FDA action.
What it does, for whom
| Drug | Role | For | NDC |
|---|---|---|---|
| Olodaterol and Tiotropium | Makes it, packages it and labels it | Boehringer Ingelheim Pharmaceuticals, Inc. | 0597-0155 |
FDA inspection history
| Ended | Result | Program | Problems noted |
|---|---|---|---|
| Jun 30, 2023 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
Registered with FDA for: analysis; label; manufacture; pack; relabel; repack.